West Cancer Center

ADVANCED SOLID TUMORS: LATE LINE: GLOBO-H POSITIVE: OBI-999-001

A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid Tumors

VIEW TRIAL ON CLINICALTRIALS.GOV

Malignancy

Pancreatic, Esophageal, Gastric, Colorectal, Breast, Lung, Prostate, Melanoma, Head and Neck, Sarcoma, Bladder, Renal Cell, Ovarian, Endometrial, Cervical

Stage

Stage 4

Phase

Phase 1

Status

Open to Enrollment

Line Of Therapy

Late line

Investigational Agent

OBI-999

Drug Class

Globo H targeting agent

Dan Vaena, MD

Sponsor

OBI Pharma

Path

Any solid tumor

Key Eligibility Criteria Details

Histologically or cytologicall confirmed patients with advanced solid tumors
Must have documented Globo H score of at least 100 from a qualified laboratory IHC assay
Must have been treated with established standard-f-care therapy or physicians have determined that such established therapy is not sufficiently efficacious or patients have declined to received standard-of-care therapy
ECOG PS 0-1
Measurable disease
Adequate organ function
No known untreated CNS mets
No significant clinical cardiac abnormality

METASTATIC SOLID TUMORS: PHASE 1 (ESCALATION): PVRIG+PD-1: CPG-01-001

A Phase 1a/1b study of COM701 as monotherapy and in combination with an anti-PD-1 antibody in subjects with advanced solid tumors.